Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines

Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector–mRNA), the influence of vaccination side effects, and the infection rate in German healthcare workers need to be investigated. Methods: In this study, 103 individuals vaccinated against SARS-CoV-2 were enrolled to examine their anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig levels. A total of 415 blood samples in lithium heparin tubes were prospectively obtained, and a structured survey regarding medical history, type of vaccine, and vaccination reactions was conducted. Results: All participants demonstrated a humoral immune response, among whom no values decreased below the positivity cutoff. Five to six months after the third vaccination, three participants showed anti-RBD/S1 antibodies of less than 1000 U/mL. We observed higher levels for heterologous mRNA-/vector-based combinations compared to pure vector-based vaccination after the second vaccination, which is harmonized after a third vaccination with the mRNA-vaccine only in both cohorts. The incidence of vaccine breakthrough in a highly exposed cohort was 60.3%. Conclusion: Sustained long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. There was longevity of anti-RBD/S1 antibodies of at least 4 and up to 7 months without external stimulus. Regarding vaccination reactogenity, the occurrence of local symptoms as pain at the injection site was increased after the first mRNA application compared to the vector–vector cohort with a general decrease in adverse events at later vaccination time points. Overall, a correlation between the humoral vaccination response and vaccination side effects was not observed. Despite the high prevalence of vaccine breakthroughs, these only occurred in the later course of the study when more infectious variants, which are, however, associated with milder courses, were present. These results provide insights into vaccine-related serologic responses, and the study should be expanded using additional vaccine doses and novel variants in the future.

[1]  J. E. Muñoz-Medina,et al.  Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population , 2023, Microbiology spectrum.

[2]  Dong Ho Kim,et al.  Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19 , 2022, Vaccines.

[3]  Howard D Larkin New Data on Heterologous COVID-19 Vaccine Combinations. , 2022, Journal of the American Medical Association (JAMA).

[4]  J. Sánchez-Payá,et al.  Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain , 2022, Vaccine.

[5]  V. Haselmann,et al.  Results of a European-Wide External Quality Assessment (EQA) Scheme for Serological Detection of Anti-SARS-CoV-2 (CoVimm)—Pitfalls of Routine Application , 2022, Viruses.

[6]  N. Toyota,et al.  Long-term observation of antibody titers against SARS-CoV-2 following vaccination , 2022, Public Health in Practice.

[7]  S. Clouston,et al.  Retrospective review COVID-19 vaccine induced thrombotic thrombocytopenia and cerebral venous thrombosis-what can we learn from the immune response , 2022, Clinical Imaging.

[8]  S. Fujitani,et al.  Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19 , 2022, Scientific Reports.

[9]  E. Ali,et al.  COVID-19 Vaccine-Induced Cerebral Sinus Thrombosis: Coincidence vs. Cause? , 2022, Cureus.

[10]  E. Undurraga,et al.  Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study , 2022, The Lancet Global Health.

[11]  Y. Poovorawan,et al.  Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data , 2022, Vaccine.

[12]  A. Apisarnthanarak,et al.  Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study , 2022, Emerging microbes & infections.

[13]  Y. Poovorawan,et al.  Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study , 2022, Human vaccines & immunotherapeutics.

[14]  D. Montefiori,et al.  Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.

[15]  B. Walker,et al.  T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals , 2022, medRxiv.

[16]  A. Hoerauf,et al.  Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines , 2021, Frontiers in Immunology.

[17]  C. Broder,et al.  Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers , 2021, Open forum infectious diseases.

[18]  Aaron M. Rosenfeld,et al.  mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern , 2021, Science.

[19]  D. Montefiori,et al.  Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report , 2021, medRxiv.

[20]  Mathias W Pletz,et al.  Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection , 2021, Viruses.

[21]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[22]  C. Castilletti,et al.  Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine , 2021, Clinical chemistry and laboratory medicine.

[23]  A. Iwasaki,et al.  Prevention of host-to-host transmission by SARS-CoV-2 vaccines , 2021, The Lancet Infectious Diseases.

[24]  J. Marschall,et al.  Serological testing for SARS‐CoV‐2 antibodies in clinical practice: A comparative diagnostic accuracy study , 2021, Allergy.

[25]  R. Scheuermann,et al.  Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.

[26]  D. Prieto-Alhambra,et al.  Heterologous vaccine regimens against COVID-19 , 2021, The Lancet.

[27]  D. O’Connor,et al.  Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2 , 2021, ImmunoHorizons.

[28]  V. Haselmann,et al.  Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection , 2021, International Journal of Infectious Diseases.

[29]  M. Sutton,et al.  Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England , 2021, BMC Medicine.

[30]  A. Griesmacher,et al.  Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers , 2021, Clinical chemistry and laboratory medicine.

[31]  P. McKay,et al.  Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice , 2021, Nature Communications.

[32]  M. Nussenzweig,et al.  Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.

[33]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[34]  Jianguo Wu,et al.  COVID-19: Coronavirus Vaccine Development Updates , 2020, Frontiers in Immunology.

[35]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[36]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[37]  F. Baldanti,et al.  Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively , 2020, Journal of Clinical Microbiology.

[38]  S. Yerly,et al.  Validation of a commercially available SARS-CoV-2 serological immunoassay , 2020, Clinical Microbiology and Infection.

[39]  P. T. Ten Eyck,et al.  Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses , 2017, Science Immunology.

[40]  Alan D. Roberts,et al.  Antibody-Independent Antiviral Function of Memory CD4+ T Cells In Vivo Requires Regulatory Signals from CD8+ Effector T Cells1 , 2001, The Journal of Immunology.

[41]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .